LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Ligand Pharmaceuticals Inc

Closed

SectorHealthcare

115.34 0.03

Overview

Share price change

24h

Current

Min

112.63

Max

116.51

Key metrics

By Trading Economics

Income

-11M

-42M

Sales

2.5M

45M

P/E

Sector Avg

47.016

50.291

EPS

1.33

Profit margin

-93.643

Employees

68

EBITDA

-11M

-41M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+27.03% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

201M

2.2B

Previous open

115.31

Previous close

115.34

News Sentiment

By Acuity

19%

81%

40 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jun 2025, 22:09 UTC

Earnings

Alimentation Couche-Tard 4Q Profit Falls on Lower Fuel Prices, Demand

25 Jun 2025, 21:19 UTC

Acquisitions, Mergers, Takeovers

Solventum Removes Drinking-Water Unit From Thermo Fisher's Planned Filtration Buy

25 Jun 2025, 20:38 UTC

Earnings

Micron Technology 3Q Profit Soars as AI Boom Boosts Sales

25 Jun 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears Over Middle East Ease -- Market Talk

25 Jun 2025, 23:39 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Uncertainties -- Market Talk

25 Jun 2025, 23:13 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Xero Probably Sees Value in Melio's Syndication Network -- Market Talk

25 Jun 2025, 23:13 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

25 Jun 2025, 21:36 UTC

Earnings

Jefferies' Profit Falls 40%. CEO Strikes Positive Tone on Dealmaking Outlook. -- Barrons.com

25 Jun 2025, 21:34 UTC

Earnings

Jefferies' Profit Falls 40%. CEO Strikes Positive Tone on Dealmaking Outlook. -- Barrons.com

25 Jun 2025, 21:23 UTC

Earnings

Micron's Profit Soars as AI Boom Boosts Sales -- Update

25 Jun 2025, 21:08 UTC

Earnings

Couche-Tard 4Q Canada Same-Store Merchandise Revenues Up 3.5% >ATD.T

25 Jun 2025, 21:07 UTC

Earnings

Couche-Tard 4Q U.S. Same-Store Merchandise Revenues Down 0.4% >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Rev $16.27B >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Adj EPS 46c >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q EPS 46c >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Net $439.4M >ATD.T

25 Jun 2025, 20:49 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:32 UTC

Earnings

FedEx Earnings Topped Estimates. The Stock Is Fell. -- Barrons.com

25 Jun 2025, 20:27 UTC

Earnings

Winnebago Stock Hits a 5-Year Low. What It Means for the RV Industry. -- Barrons.com

25 Jun 2025, 20:26 UTC

Earnings

These Stocks Moved the Most Today: BP, FedEx, QuantumScape, BlackBerry, Nvidia, AeroVironment, and More -- Barrons.com

25 Jun 2025, 20:24 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:10 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:04 UTC

Earnings

Micron Technology Sees 4Q Adj EPS $2.35-Adj EPS $2.65 >MU

25 Jun 2025, 20:04 UTC

Earnings

Micron Technology Sees 4Q EPS $2.14-EPS $2.44 >MU

25 Jun 2025, 20:03 UTC

Earnings

Micron Technology Sees 4Q Rev $10.4B-$11B >MU

25 Jun 2025, 20:02 UTC

Earnings

Micron Technology: On Track to Deliver Record Rev With Solid Profitability and Free Cash Flow in FY25 >MU

25 Jun 2025, 20:02 UTC

Earnings

Micron Technology: Record Rev in Fiscal 3Q With Growth Across End Markets >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q Net $1.89B >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q Adj EPS $1.91 >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q EPS $1.68 >MU

Peer Comparison

Price change

Ligand Pharmaceuticals Inc Forecast

Price Target

By TipRanks

27.03% upside

12 Months Forecast

Average 147 USD  27.03%

High 157 USD

Low 135 USD

Based on 6 Wall Street analysts offering 12 month price targets forLigand Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

102.5 / 109.24Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

40 / 380 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.